Document:

Exhibit 10.41

***Text Omitted and Filed
Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 240.24b-2.

C O N F
I D E N T I AL

AMENDMENT
TO COLLABORATION AGREEMENT

THIS
AMENDMENT TO COLLABORATION AGREEMENT (the “Amendment”) is
entered into and effective as of October 31, 2006 (the “Amendment Date”) for
the purpose of amending that certain Collaboration Agreement dated September
19, 2002, as amended (the “Agreement”)
by and between:

ELI LILLY AND
COMPANY, a corporation organized and existing under the laws
of the State of Indiana, whose principal place of business is Lilly Corporate
Center, Indianapolis, Indiana, 46285, United States of America (“Lilly”); and

AMYLIN PHARMACEUTICALS, INC., a
corporation organized and existing under the laws of Delaware, whose principal
place of business is 9360 Towne Centre Drive, San Diego, California 92121,
United States of America (“Amylin”).

In consideration of the mutual covenants contained
herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, Lilly and Amylin agree as follows:

1.             Defined
Terms.  Capitalized
terms used but not otherwise defined herein shall have the meanings provided in
the Agreement.  Any reference herein to a
numbered “Section” shall be deemed to refer to such numbered Section of the
Agreement, and any reference herein to a numbered “paragraph” shall be deemed
to refer to such numbered paragraph of this Amendment.  The following terms shall have the meanings
set forth below:

(a)           “BID
Product” shall mean the Product sold under the Product Trademark “BYETTA®”
(or such other Trademark if BYETTA is unavailable as a Trademark in a given
country) as a fixed-dose injection of exenatide administered twice per day for
any indication provided for in the first Marketing Approval received in a
relevant country (included in such indication would be any subsequent label
expansion(s)  relating to use of the BID Product for the
same indication, e.g., new
indication for combination use with TZDs for treatment of the same indication
as provided for in the first Marketing Approval). For the avoidance of doubt,
it is understood that any subsequent indication relating to any disease or
condition not included in the first Marketing Approval shall be regarded as a
Non-BID Product (e.g., a Product indicated for treatment of obesity or Type I
diabetes is a Non-BID Product).

(b)           “BID Study” shall mean
a clinical trial of a BID Product; but excluding any Non-BID Study.

(c)           “Cost of
Product Sold (OUS)” shall mean, solely for purposes of
calculation of Gross Margin (OUS) and for no other purpose, the Cost of Product
Sold for Product sold outside the U.S., determined in accordance with Section
1.33 of the Agreement, plus Lilly’s manufacturing costs for labeling,
packaging, or other manufacturing-related activity that may be undertaken by
Lilly for Product sold outside the U.S. 
Lilly’s manufacturing costs included in Cost of Product Sold (OUS) shall
include, without limitation, the standard cost of product sold expensed by
Lilly for Product sold outside the U.S. plus manufacturing variances expensed
by Lilly for Product sold outside the U.S., in each case, determined in
accordance with U.S. GAAP.   It is understood
that Lilly’s Cost of Product Sold (OUS) may or may not be the same as Lilly’s
internal transfer pricing to its Affiliates for Product sold outside of the
U.S. and Lilly’s Cost of Product Sold (OUS) shall not include any mark-up or
profit margin in addition to actual Product cost.

Lilly’s standard cost of
product sold may include, without limitation, the following components:

(i)               the total
invoice price, outside processing costs, freight, duties, taxes, and brokers
fees, with any volume or trade discounts being reflected in the calculation and
purchase of inventory from either Amylin or Third Party suppliers being
considered a Third Party cost;

(ii)             conversion
costs (including, without limitation, direct labor and direct overhead)
directly associated with the manufacturing of Product;

(iii)            replacement
costs for Products that are determined to be defective or recalled or for
Products that are returned to Lilly from the customer;

(iv)             an
allocation of service and administrative departments performing functions which
support Manufacturing operations directly associated with the Manufacturing of
Products;

(v)              depreciation
of Product-specific capital investments for equipment;

(vi)             depreciation
of general manufacturing equipment and facilities directly associated with
Manufacturing of Products, in the case of equipment, to the extent used
specifically for Product, based on a percentage of throughput/utilization
(hours of utilization) and, in the case of facilities, based upon percentage of
square footage utilized.

(vii)            Product
breakage;

 2
 

(viii)          obsolete
Products; and

(ix)             to the
extent attributable to the Manufacture of Products, any other costs considered
inventory costs or costs of products sold under U.S. Generally Accepted
Accounting Principles.

  All of these costs, and the methodology to be
used in allocating indirect or overhead costs among Manufacturing operations
hereunder and other Lilly manufacturing operations, shall be determined in a
manner consistent with Generally Accepted Accounting Principles in the U.S.,
and Lilly shall share with Amylin such details relating to the allocation
relating to operations outside the U.S. used by Lilly as Amylin may reasonably
request.  In the event that Lilly does
not use Dedicated Capacity for primary equipment for the Manufacture of
Products, an appropriate allocation of costs associated with the Manufacture of
Products shall be determined in a manner consistent with Generally Accepted
Accounting Principles in the U.S.  It is
understood and agreed by the Parties that Lilly will report all costs using its
then current systems and procedures, subject to audit and adjustment as
required to be consistent with this Amendment.

(d)           “Cumulative
Gross Margin (OUS)” shall mean the cumulative Gross Margin
(OUS) calculated beginning upon the first Product Launch for Product outside
the U.S.

(e)           “Gross
Margin (OUS)” shall mean Net Sales of Products outside
the U.S., less: (i) Cost of Product Sold (OUS) and (ii) Product Sample Costs
for Product Samples supplied for distribution outside the U.S.   Notwithstanding the foregoing, for purposes of
calculating Gross Margin (OUS), in no event shall Product Sample Costs for
Product Samples distributed outside the U.S. exceed commercially reasonable
sample quantities.

(f)            “Major
OUS Market” shall mean the following countries:  France, Germany, Italy, Spain, United
Kingdom, and Japan.

(g)           “Non-BID
Product” shall mean a Product other than BID Product.

(h)           “Non-BID
Study” shall mean a clinical trial of a BID Product that compares
a Non-BID Product to a BID Product or that includes a Non-BID Product.

(i)            “Non-Major
OUS Market” shall mean any country outside the U.S.
that is not a Major OUS Market.

(j)            “OUS BID
Development Trial Costs” shall mean Development Costs
specifically attributable to all BID Studies (excluding BID Studies that are
not required for Marketing Approval such as Phase 3B Clinical Trials and Phase
4 Clinical Trials), other than any such BID Study that is required to be
undertaken to obtain Marketing Approval of BID Product in the U.S.

 3
 

(k)           “OUS BID
Commercialization Trial Costs” shall mean Commercialization Costs
specifically attributable to all BID Studies undertaken to support
Commercialization outside the U.S. that are not required for Marketing Approval
such as Phase 3B Clinical Trials and Phase 4 Clinical Trials.

(l)            “OUS
Non-BID Development Trial Costs” shall mean Development Costs
specifically attributable to all Non-BID Studies (excluding Non-BID
Studies that are not required for Marketing Approval such as Phase 3B Clinical
Trials and Phase 4 Clinical Trials), other than any such Non-BID Study that is
required to be undertaken to obtain Marketing Approval of Non-BID Product
in the U.S.

(m)          “OUS
Non-BID Commercialization Trial Costs” shall mean
Commercialization Costs specifically attributable to all Non-BID
Studies  undertaken to support
Commercialization outside the U.S. that are not required for Marketing Approval
such as Phase 3B Clinical Trials and Phase 4 Clinical Trials.

(n)           “Product Plan” shall mean, for a particular
Major OUS Market, the strategic and tactical medical, marketing and sales plans
for Product(s) of the type and format used from time to time by Lilly for its
own products. For the avoidance of doubt, as of the Amendment Date, the
referenced plans are known internally as “Lilly Affiliate Brand Plans.”

(o)           “Product
Sample” shall mean a sample (or a voucher for a sample) of Product
supplied for distribution to health care professionals without charge for
promotional, patient initiation, or familiarization purposes.

(p)           “Product
Sample Costs” shall mean the standard unit cost plus
variances of Product Samples actually distributed in a country after Marketing
Approval in such country, calculated in accordance with GAAP samples  accounting methods, consistently applied.    Distribution costs shall be excluded from
the standard unit cost.  However, Product
Sample Costs will be included in the Cost of Product Sold (OUS) (rather than in
the marketing and  selling expense line), and shall
reflect the standard Cost of Product Sold plus variances.

2.             Allocation
of OUS Revenues.  Effective
for OUS revenues accrued on or after January 1, 2007,  Section 4.5(b) of the Agreement shall be eliminated in its
entirety and replaced with the royalty-based structure set forth in this paragraph
2, pursuant to which Lilly will retain all revenues from sales of Product in
the Territory outside the U.S. and pay a royalty to Amylin based upon a
percentage of Gross Margin (OUS). 
Commencing on the date when Cumulative Gross Margin (OUS) exceeds $[***]
and continuing during the term of the Agreement, Lilly shall pay to Amylin
royalties based on the aggregate annual Gross Margin (OUS) (without adjustment
for partial calendar years) at the rates set forth below:

(a)           [***]% of
the portion of aggregate Gross Margin (OUS) during a calendar year that is
equal to or less than $[***];

(b)           [***]% of
the portion of aggregate Gross Margin (OUS) during a 

***CONFIDENTIAL
TREATMENT REQUESTED

 4
 

calendar
year that is greater than $[***] but equal to or less than $[***]; and

(c)           [***]% of
the portion of aggregate Gross Margin (OUS) during a calendar year that is
greater than $[***] but equal to or less than $[***]; and

(d)           [***]% of
the portion of aggregate Gross Margin (OUS) during a calendar year that is greater
than $[***].

For
the avoidance of doubt, the Parties acknowledge and agree that no royalty shall
be due on the first $[***] of Cumulative Gross Margin (OUS), nor shall such
amount be included in determining the applicable royalty rates set forth above.  The exclusion of the first $[***] in
Cumulative Gross Margin (OUS) is to be applied one time and not on a
product-by-product or country-by-country basis. 
The following sample calculation is provided for purposes of
illustration and clarification only:

 

	
  

  Year

  	
   

  	
  Annual Gross 

  Margin (OUS)

  	
   

  	
  Cumulative Gross 

  Margin (OUS)

  	
   

  	
  Royalty Payable 

  to Amylin

  	
   

  
	
  2006

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  2007

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  2008

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  2009

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***] (1)

  	
   

  
	
  2010

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***] (2)

  	
   

  

(1)During [***], Cumulative Gross
Margin (OUS) first exceeds $[***], and calculation of royalties payable with
respect to Gross Margin (OUS) in excess of $[***] (i.e., $[***]) begins. The
royalty for [***] would therefore equal $[***] x [***]%, or $[***].

(2)For [***] (the year after
Cumulative Gross Margin (OUS) first exceeds $[***]), the royalty payable would
be calculated as follows: ($[***] x [***]%) + ($[***] x [***]%) = $[***].

Also
effective as of January 1, 2007, all references to “Adjusted OUS Operating
Profit/Loss” in Section 4.9 (a) shall be deleted, and the “OUS Operating Profit
Sharing” example calculations found in Schedule 4.5 shall be deleted in their
entirety.  Royalties due under this
paragraph 2 shall be paid by Lilly to Amylin on a [***] basis within [***]
([***]) days after the end of [***] for Products sold outside of the U.S.
during such [***].  At Lilly’s option,
such payment may be made by providing Amylin a credit in the amount of the
royalty due as part of the calculation of periodic settlement payments between
the Parties contemplated by Section 4.9(a). 
Royalties due each [***] under this paragraph 2 shall be subject to
simple interest as follows:  royalties
due from Product sales from the [***] of each [***] shall be increased by an
amount equal to simple interest for a period of [***], and royalties due from
Product sales from the [***] of each [***] shall be increased by an amount
equal to simple interest for a period of [***]. 
The interest factor used for a particular [***] shall be equal to the
rate specified in the Agreement for calculating amounts owed under Section
4.9(a) (as described in the letter agreement between the Parties dated June 12,
2006.)

3.             Allocation
of OUS Development and Commercialization Costs. 
In partial 

***CONFIDENTIAL
TREATMENT REQUESTED

 5
 

consideration
of Amylin foregoing its right to receive any share of the first $[***] of
Cumulative Gross Margin (OUS), the Parties hereby agree to the following
allocations with respect to costs outside the U.S.:

(a)           BID
Products.  Lilly shall be solely responsible for 100% of
BID Product Commercialization Costs relating to the Commercialization of BID
Products outside of the U.S. (including without limitation OUS BID
Commercialization Trial Costs), and regardless of whether such
Commercialization Costs were incurred before or after the Amendment Date.
Effective as to expenses accrued on or after January 1, 2007, Lilly shall also
be solely responsible for 100% of BID Product Development Costs relating to Development
of BID Product for sale outside of the U.S. (including without limitation OUS
BID Development Trial Costs). 
Accordingly, BID Product Commercialization Costs relating specifically
to sale of Product outside of the U.S., and effective January 1, 2007, BID
Product Development Costs specifically relating to development of BID Product
for sale outside of the U.S., shall not be included in the calculation of the
periodic settlement payments between the Parties contemplated by Section 4.9(a)
of the Agreement.  Exhibit C sets forth
those clinical trials or other development activities underway as of the
Amendment Date and indicates how the expenses thereof shall be shared by the
Parties, subject to potential adjustment as provided in Paragraph 3(c).   For the avoidance of doubt, it is understood
that any Development Costs related to development of Non-BID Product for sale
outside the US shall continue to be allocated 80% to Lilly and 20% to Amylin as
contemplated by Section 4.3(a)(ii) of the Agreement.  It is also understood that Amylin shall not
be entitled to reimbursement of any OUS BID Product Commercialization Costs  unless reimbursement is approved in advance by Lilly.

(b)           Non-BID
Products.  Section 4.4(a)(ii) of the Agreement is amended
in its entirety, effective January 1, 2007, to read as follows:

“(ii)   Rest of World.  Lilly shall pay one hundred percent (100%) of
the Commercialization Costs for Commercialization of Products in all countries
in the Territory outside the U.S. and Amylin shall pay 0% of such
Commercialization Costs, with the sole exception of OUS Non-BID
Commercialization Trial Costs which shall be allocated 80% to Lilly and 20% to
Amylin.”

***CONFIDENTIAL TREATMENT
REQUESTED

 6
 

 

Lilly will prepare and
deliver to Amylin, in addition to and concurrently with the [***] composite
reports due pursuant to Section 4.9(a), a separate composite report of OUS Non-BID
Commercialization Trial Costs substantially the same in scope, content and
format to the [***] reports of Development Costs due pursuant to Section
4.3(b), and the amounts reported in such composite report of OUS Non-BID
Commercialization Trial Costs shall be aggregated with the amounts reported in
the composite reports specified in Section 4.9(a) and included in the
calculation of periodic settlement payments between the Parties contemplated by
Section 4.9(a).  The parties recognize
that Lilly does not formally track time spent by OUS FTE’s on Development
matters versus time spent by the same individuals on Commercialization matters so
that good faith allocations of FTEs between the categories of Non-BID
Commercial Trial Costs and Non-BID Development Trial Costs may be necessary.

(c)           Costs for OUS Studies
Utilized in U.S.

(i)                                    The
Parties recognize that data from certain clinical, health outcomes or other
studies undertaken for Development or Commercialization purposes relating to
countries outside the U.S. (an “OUS Study”) may generate data that could also
be utilized for U.S. purposes. 
Accordingly, the Parties agree as follows:

a.               Except with respect
to any Required Study, the Global Development and Commercialization Committee (“GDCC”)  shall, prior to the initiation of any OUS Study, review
whether such OUS Study is also expected to generate data that will be utilized
for U.S. purposes.  If the GDCC agrees
that the OUS Study will also be used for U.S. purposes, (a “Dual Use Study”)
then the expense of such Dual Use Study shall be shared in accordance with the
Dual Use Cost Allocation. In all other cases, the expenses of the OUS Study shall
be shared in accordance with the OUS Study Cost Allocation, but shall be
subject to possible later recharacterization as provided in paragraph (d)
below. The Parties agree that their respective representatives to the GDCC will
act in a reasonable manner with respect to any proposal that an OUS Study be
regarded as a Dual Use Study.

b.              Except as provided
in paragraph (c) below, if the OUS Study is a Required Study, the expenses
thereof shall be shared in accordance with the OUS Study Cost Allocation regardless
of whether such OUS Study is also used in the U.S., and the provisions of
paragraph (d) below shall not apply.

c.               Notwithstanding
paragraph (b) above, any OUS Study relating to Non-BID Product that is a
Required Study for Marketing Approval in the European Union (“Europe Non-BID
Product Registration Study”) shall be prospectively reviewed by the GDCC upon
request of either Party to determine whether data from such Europe Non-BID
Product Registration Study is also expected to be used for U.S. purposes.  If the GDCC agrees 

***CONFIDENTIAL
TREATMENT REQUESTED

 7
 

that data from such Europe Non-BID Product
Registration Study will be used for U.S. purposes, then such study shall be
deemed a Dual Use Study and the expenses thereof shall be shared in accordance
with the Dual Use Cost Allocation.  In
all other cases, the expense of the Europe Non-BID Product Registration Study
shall be shared in accordance with the OUS Study Cost Allocation, but shall be
subject to possible later recharacterization as provided in paragraph (d)
below.  The Parties agree that their
respective representatives to the GDCC will act in a reasonable manner with
respect to any proposal that an OUS Study be regarded as a Dual Use Study.

d.              With respect to (i)
any OUS Study that is not a Required Study and that has not previously been
determined to be a Dual Use Study and (ii) any Europe Non- BID Product
Registration Study that has not previously been determined to be a Dual Use
Study, either Party shall have the right to request that the allocation of
costs of any such study be reviewed based upon actual or intended use or
non-use (as defined below in (c) (iii)) of the data therefrom.  In the event either party requests such a
review, the GDCC shall review such issue in good faith, and if it concludes
that the study is a Dual Use Study the expenses of such study previously
incurred shall be reallocated as appropriate in accordance with the Dual Use
Study Cost Allocation. If necessary, an appropriate adjustment shall be made in
the next [***] settlement contemplated by Section 4.9 of the Agreement.  Thereafter, any future expenses of such study
shall be shared in accordance with the Dual Use Cost Allocation, and
appropriately reflected in the [***] settlement.  The Parties agree that their respective
representatives to the GDCC will act in a reasonable manner with respect to any
proposal that data from an OUS Study be used in the U.S. In the event the GDCC
is unable to agree upon proposed U.S. use of data from an OUS Study, Lilly may
if applicable exercise its right under of Section 3.1(e) (ii) to require that
data from an OUS Study be utilized in the U.S., but if Lilly exercises such
right, the fact that such data was used in the U.S. shall not be a basis for
recharacterization of the expenses of such OUS Study.

(ii)                                As
used herein:

a.               “OUS Study Cost
Allocation” shall mean (i) in the event such expenses are related to a BID
Product and incurred prior to January 1, 2007, the expenses shall be borne 80%
by Lilly and 20% by Amylin, (ii) in the event such expenses are related to a
BID Product and incurred on or after January 1, 2007, the expenses shall be
borne 100% by Lilly, and (iii) in the event such expenses are related to
Non-BID Product (regardless of whether such expenses are incurred before or
after January 1, 2007), the expenses shall be borne 80% by Lilly and 20% by
Amylin.

***CONFIDENTIAL
TREATMENT REQUESTED

 8

b.              “Dual Use Cost
Allocation” shall mean 50% of such expenses are borne by Lilly and 50% by
Amylin.

c.               “Required Study”
shall mean any study required as part of the minimum data package necessary for
receipt of Marketing Approval in the relevant country.  The Parties recognize that the application
for Marketing Approval may include additional OUS Studies that are useful, but
not required, and that any such additional study shall not be deemed a Required
Study.

(iii)                            Data
will be considered utilized for U.S. purposes if such data is (i) contained in
materials approved for use in the U.S. by any joint U.S. promotion or U.S.
medical/legal/regulatory review body established by the Parties (e.g., the
committee currently known as SMART), (ii) 
included in materials utilized by U.S. sales representatives, medical
liaisons, or managed care account representatives, such as promotional slide
sets, materials for use in health professional to health professional programs,
marketing materials, brochures, or authorized reprints utilized by alliance
personnel in field or congress settings, (iii) is disclosed for U.S.
promotional purposes at U.S. congresses or in U.S. publications or (iv)
included in any direct to consumer advertising or consumer directed promotional
materials distributed in the U.S.  Data
will not be considered utilized for U.S. purposes merely because such data is
(i) used in Third Party U.S. continuing medical education programs, (ii)
released by Lilly in U.S. venues  or U.S.
publications to service OUS needs, (iii) used with advisory boards,  (iv) filed as required with U.S. Regulatory
Authorities (but not any pivotal studies) , (v) used in medical information
letters, used to answer unsolicited medical questions, used in reprints used at
congresses to answer unsolicited medical questions, (vi) used in scientific
slide decks provided only upon request, (vii) presented at Lilly’s request in
poster or abstract form at scientific meetings or congresses or by independent
investigators where such presentation was not requested by Lilly, or (viii) any
meta based data analysis.

(iv)                               The
provisions of Section 4.3(a)(iii) of the Agreement shall continue in effect.

(d)  [***] Report
Adjustment.  The Parties
have previously disagreed as to the responsibility for certain OUS
Commercialization Costs.  In order to
resolve this dispute,  the periodic
settlement payment contemplated by Section 4.9(a) of the Agreement due to Lilly
for the [***] after the Amendment Date will include an additional $[***] beyond
any actual amount due to Lilly, for such [***], with the effect that the amount
that would otherwise be due to Lilly will be increased by $[***].  All future OUS Commercialization Costs shall
be borne by Lilly as provided in paragraph 3.

(e)           Conforming
Changes.  

(i)            Section
8.1(c) of the Agreement is hereby amended to read

***CONFIDENTIAL
TREATMENT REQUESTED

 9
 

in
its entirety as follows:  “In the event
of any product liability or other Third Party claim in which both Parties are
asserted to be liable and neither is entitled to indemnification hereunder, the
Parties shall treat such Damages as Commercialization Costs if such claim
relates to the U.S. or share such Damages 80% by Lilly and 20% by Amylin if
such claim relates to the Territory outside the U.S.  In the case of any such claim relating to the
Territory outside the U.S., (i) any amounts owed to Lilly pursuant to this
Section 8.1(c) shall be paid as part of the periodic settlement process
contemplated under Section 4.9(a) of the Agreement and (ii) in the event such amount
is due to Lilly at anytime prior to the expiration of one year from the date of
the first Product Launch in the first country outside the U.S., the amount due
to Lilly shall initially be treated as a credit against royalties due from
Lilly hereunder for such first year, and thereafter any remaining amount due
shall be paid through the periodic settlement process for the [***] immediately
following such first year. ”

(ii)           Section
10.4(e) of the Agreement is hereby amended to read in its entirety as follows:  “Each Party shall pay 50% of any expenses
(except for the expenses of the non-controlling Party’s counsel, if any) and
shall receive 50% of any recovery realized as a result of any litigation
pursuant to this Section 10.4 until each Party’s reimbursable expenses have
been recovered and thereafter share recovery in accordance with each Party’s
proportionate interest in Operating Profits and Losses for the U.S., or if such
litigation relates to the Territory outside the U.S., 80% to Lilly and 20% to Amylin.”

4.               Audit
Rights. 
The Parties acknowledge each Party’s right to audit under Section 4.9(e)
of the Agreement shall include the right to audit any Affiliates of the other
Party as part of an audit where a Party audits the U.S. and/or one or more
countries outside the U.S.  It is
understood that for purposes of determining responsibility for payment of audit
expenses pursuant to Section 4.9(e), the 5% materiality threshold shall be
applied to the U.S. and any audited OUS countries taken as a whole.

5.               Reporting.          (a) Lilly shall provide royalty reporting to Amylin in a form to be mutually
agreed by the Parties.  Royalty reporting
shall be provided [***] together with royalty payments.  Lilly also agrees to undertake [***] updates
to Amylin in any [***] where Lilly anticipates material variances so as to
allow Amylin to make financial adjustments in its financial reporting.  It is the Parties’ intention to structure
reports to fulfill Amylin reporting needs and be as consistent as possible
within existing internal Lilly systems to the extent practical to do so.  Attached hereto as Exhibit A and
described below are examples of the royalty reports to be provided.

(b)           Lilly
shall provide Amylin with the following reports:

(i)            a
[***] royalty report substantially in the form of Exhibit A within [***] ([***]) days of [***].

(ii)           [***] planning report(s) as follows:

***CONFIDENTIAL
TREATMENT REQUESTED

 10
 

(A)    showing
a preliminary [***] ([***]) year royalty projection by country for Major OUS
Markets and in the aggregate for all other countries, the timing of such report
to be consistent with the alliance financial calendar agreed upon by the GDCC
each year; and

(B)    showing
a final [***] ([***]) year royalty projection by country for Major OUS
Markets and in the aggregate for all other countries, the timing of such report
to be consistent with the alliance financial calendar agreed upon by the GDCC
each year;

(iii)         [***]
rolling forecasts showing projections of [***] within [***] days after the
forecasts are finalized each [***] by Lilly.

Lilly represents and warrants that Exhibit B to this
Amendment fairly and accurately describes how Lilly currently calculates
foreign currency conversions as referenced in Section 4.9(a) of the
Agreement.  It is understood that Lilly
may from time to time change its methodology for currency conversions.

6.          OUS
Commercialization Activities.  Lilly shall have responsibility for
Commercialization activities outside the U.S., including development, approval
and implementation of the Commercialization Plan as it relates to the Territory
outside the U.S. (the “OUS Commercialization Plan”).  Amylin will have advisory input into the OUS
Commercialization Plan, but all decisions as to the content of the OUS
Commercialization Plan, the OUS Commercialization Budget, and the
Commercialization activities to be conducted outside the U.S. shall be made by
Lilly, provided, however, that Lilly shall comply with its obligations under
the Agreement as modified by this Amendment. 
Notwithstanding the foregoing, any portion of the Commercialization Plan
specifically relating to Non-BID Commercialization Trial Costs shall be subject
to the approval pursuant to the Binding Budget process of the Agreement. Nothing in this Amendment shall be construed as modifying the
provisions in the Agreement related to Manufacturing or to selection of
trademarks, or any other rights that are not specifically changed by
this Amendment, all of which shall
continue in effect, or any other right of review, approval or participation of
Amylin under the Agreement except to the extent specifically provided in this
Amendment. The terms of the Clinical
Research Quality Agreement between the Parties dated May 14, 2004 shall
continue in effect. Through the GDCC, Amylin and Lilly agree to modify the
roles and responsibilities guidance for activities outside of the U.S. such
that Amylin retains its current participation in the Lilly Brand Council I and
II processes.  In addition, GDCC will
modify the OUS roles and responsibilities to maintain Amylin’s current ability
to review and provide input into the Affiliate Brand Plans for the Major OUS
Markets.  Lilly and Amylin anticipate the
OUS roles and responsibilities document will be updated to include the following
topics.

·                              Addition of
Amylin Medical and Team management into the Brand Council I and II process.

***CONFIDENTIAL
TREATMENT REQUESTED

 11
 

·                              Clarification
of Amylin’s ability to review and provide input on OUS Major Market affiliate
plans versus review and input of Non-Major OUS Market affiliate plans.

·                              Clarification
of a Brand Council III alliance process that provides Amylin representatives
the appropriate venue and access to personnel to review and provide input on
OUS Major Market affiliate plans.

(a)           Non-Major
OUS Markets.  If Amylin has business questions regarding
brand management for Product(s) in any Non-Major OUS Market, Lilly’s
representatives shall address such questions on an ad hoc basis to the extent
included as approved GDCC agenda items.

(b)           Budget
Summary.  Consistent
with the Brand Council Process and Product Plans of Lilly Affiliates, Lilly
will provide to Amylin on an [***] basis, a budget summary covering the next
[***] for each of the Major OUS Markets in such level of detail and format as
the parties shall agree.  Such summaries
shall include external marketing and medical spending as well as sales force
FTEs.  It is understood that any such
budget shall reflect Lilly’s plans at the time such budget is created but shall
not be binding upon Lilly.  Each such
budget summary may be modified from time to time by the applicable Lilly
Affiliate, but Lilly shall provide to Amylin a final Lilly-approved copy that
represents the next year’s approved budget plan for such Major OUS Market
promptly following approval of such plan.

(c)           Long Range Business Plan. 
[***], Lilly shall present to Amylin a long-range business plan for
Commercialization of Products outside the U.S., including [***].  Such long-range business plans shall be presented
for each Major OUS Market and in summary fashion for all Non-Major OUS
Markets.  In addition, the business plan
shall also include, at an OUS consolidated level, [***].

(d)           Budget
Summary and Business Plan Updates.  In the [***], Lilly shall provide Amylin
(through the GDCC) with updates of the annual budget summary delivered to
Amylin pursuant to paragraph 6(b) and any material update to the business plan
for the Products.  Each such update shall
cover the [***].  The budget summary
updates will include, without limitation, [***].  In the budget summary updates, for any [***]% or greater discrepancy (provided the discrepancy is
at least $[***]) between actual and
forecasted amounts, Lilly shall also provide brief explanatory comments
regarding the reason(s) for such discrepancy. 
At Amylin’s reasonable request, additional discussions and/or questions
relating to such updates shall occur to
the extent approved as a GDCC topic.

(e)           Existing
Obligations.   The Parties existing obligations under
Sections 2.2 and 2.6 of the Agreement shall be deemed modified as necessary to
be consistent with the provisions of this Amendment.

7.             Exclusions
from Binding Budgets.  The Parties agree that Development Costs

***CONFIDENTIAL
TREATMENT REQUESTED

 12
 

outside the U.S. and
Commercialization Costs outside the U.S. that are borne entirely by Lilly are
not subject to the provisions of the Agreement that are specifically applicable
to Binding Budgets.  This provision shall
not relieve Lilly from the obligation to use Commercially Reasonable Efforts to
Commercialize the Products on a worldwide basis as provided in the Agreement.

8.          Medical
Meetings.

(a)           Lilly
Meetings.  To the extent that certain Lilly-organized medical meetings relating to
commercialization of Product OUS contain sections on Product, Lilly shall invite
Amylin to attend the specific sections related to Product and provide Amylin
with at least [***] prior written notice of such meetings.  For purposes of clarity, this paragraph shall
be applicable only to the following global and regional conferences (or any
successor conferences covering substantially the same topics):

(i)            European Clinical Advisory Boards;

(ii)           Global Medical Conferences (GMC’s);

(iii)         Regional Medical Conferences (RMC’s); and

(iv)          Taking Control Peaks and Valleys Conferences (TCPV).

(b)           Amylin
Meetings.  To the extent that certain Amylin-organized medical meetings contain
sections on Product, Amylin shall invite Lilly to attend the specific sections
related to Product and provide Lilly with at least [***] prior written notice
of such meetings.  For purposes of
clarity, this paragraph shall be applicable only to the following meetings (or
any successor meetings covering substantially the same topics):

(i)            Amylin’s non-US medical meetings; and

(ii)           Amylin’s non-US advisory board meetings.

9.                              Recalls.  Section 3.1(e)(ii) (A) of the Agreement is hereby
deleted.  Section 5.11 of the Agreement
is hereby amended to read in its entirety as follows:

“In the event either Party
believes that a recall or removal from the market of the Product is necessary
in any Regulatory Jurisdiction, it shall immediately notify the other Party,
and the Parties shall discuss the appropriate course of action.  In the event of any disagreement between the
Parties regarding the necessity of a recall or removal, the Marketing Approval
holder for the Regulatory Jurisdiction in question shall make the final
determination after considering in good faith the views of the other
Party.  In the event that a Regulatory
Authority issues a request, directive, or order, or the Marketing Approval
holder determines to recall or remove the Product from the market, the recall
shall be the responsibility of the Marketing Approval holder.  Both Parties will cooperate fully with one
another in conducting the recall.”

***CONFIDENTIAL
TREATMENT REQUESTED

 13
 

10.        Entire
Agreement.  The Agreement, as amended by this Amendment, embodies the entire
understanding of the Parties and shall supersede all previous communications,
representations and understandings, whether oral, written or otherwise, between
the Parties relating to the subject matter hereof.  Except as specifically amended by this
Amendment, the terms and conditions of the Agreement shall remain in full force
and effect.

11.        Governing
Law.  This Amendment shall be governed by, and construed and enforced in
accordance with, the laws of the State of New York, excluding its conflicts of
laws principles.

12.        Counterparts.  This Amendment may be
executed in counterparts, each of which shall be deemed an original document,
and all of which, together with this writing, shall be deemed one instrument.

IN WITNESS WHEREOF, the
Parties hereto have duly executed this Amendment as of the Amendment Date.

	
  ELI LILLY AND COMPANY

  	
   

  	
  AMYLIN PHARMACEUTICALS, INC.

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Bryce D. Carmine

  	
   

  	
  By:

  	
  /s/ Daniel M. Bradbury

  
	
   

  	
   

  	
   

  
	
  Name:

  	
  Bryce D. Carmine

  	
   

  	
  Name:

  	
  Daniel M. Bradbury

  
	
   

  	
   

  	
   

  
	
  Title:

  	
  President, Global Brand Dev.

  	
   

  	
  Title:

  	
  President and Chief Operating
  Officer

  
									

 

 14

EXHIBIT A

REPORTS

 

 

	
  Byetta OUS Gross
  Margin Royalty Calculation

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  For the
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Country/Affiliate

  	
   

  	
  

  Net Sales

  	
   

  	
  Foreign

  Exchange Rate

  	
   

  	
  

  Net Sales

  	
   

  	
  Std. Cost

  COPS

  	
   

  	
  Std. Cost

  Samples

  	
   

  	
  Gross

  Margin

  	
   

  
	
   

  	
   

  	
  Local Currency

  	
   

  	
   

  	
   

  	
  US Dollars

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $[***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  

 

	
  OUS Distribution

  	
    [***]

  
	
  OUS Mfg
  Variances - favorable/(unfavorable)

  	
  $[***]

  
	
   

  	
   

  
	
  Total PUS Gross
  Margin

  	
  $[***]

  
	
   

  	
   

  
	
  OUS
  G.M. Royalty*

  	
  $[***]

  

 

*Illustrative only — early years will also have to reflect adjustment
for cumulative

gross margin on which no
royalty will be due.

***CONFIDENTIAL
TREATMENT REQUESTED

Byetta 5mcg Sales
Supplemental

For the [***]

All in [***]

	
  

  Country/Affiliate

  	
   

  	
  

  Sales Units

  	
   

  	
  

  Net Sales

  	
   

  	
  Foreign

  Exchange

  Rate

  	
   

  	
  

  Net Sales

  	
   

  	
  Std. Cost

   COPS

  	
   

  
	
   

  	
   

  	
  Local Currency

  	
   

  	
   

  	
   

  	
  US Dollars

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  In mils

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
   

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  

 

***CONFIDENTIAL
TREATMENT REQUESTED

 

 2
 

Byetta 10mcg Sales Supplemental

For the [***]

	
  Country/Affiliate

  	
   

  	
  Sales Units

  	
   

  	
  Net Sales

  	
   

  	
  Foreign

  Exchange

  Rate

  	
   

  	
  Net Sales

  	
   

  	
  Std. Cost

   COPS

  	
   

  
	
   

  	
   

  	
  Local Currency

  	
   

  	
   

  	
   

  	
  US Dollars

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  in mils

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  
	
   

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $[***]

  	
   

  	
  $[***]

  	
   

  

 

Byetta Samples Supplemental

For the [***]

 

	
  

  Country/Affiliate

  	
   

  	
  

  Sample Units

  in mils

  	
   

  	
  

  	
   

  	
  

  	
   

  	
  Std. Cost

  Samples

  in mils

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $[***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [***]

  	
   

  	
   

  
	
   

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $[***]

  	
   

  	
   

  

 

***CONFIDENTIAL
TREATMENT REQUESTED

 3
 

EXHIBIT B

Lilly Foreign Currency Conversion Methodology

Month
end FX spot exchange rates are pulled from a reliable source, or calculated by
the affiliate when required for statutory purposes, at each month end and
loaded into Lilly Enterprise System. 
These rates are used to translate income statement totals into U.S.
dollars for reporting purposes in the subsequent month.  For example, the EUR/USD spot exchange rate
pulled on or near April 30 becomes the rate for translation of income statement
transactions recorded during the month of May for all EUR-denominated
subsidiaries for consolidated reporting purposes.  The end result is a weighted average exchange
rate being used to convert foreign currency income statement totals into U.S.
dollars throughout the quarter/year. 
Except as may otherwise be required by law, these rates shall conform to
an independent worldwide exchange rate authority such as Reuters or the Wall
Street Journal (based on rates posted on or near the last business day of the
applicable month).

 

 4

EXHIBIT C

Ongoing Development and Commercialization Study Costs*

	
   Trial/Study
  Description

  	
   

  	
  US Split

  50/50

  	
   

  	
  OUS Split

  80L/20A

  	
   

  	
  Beginning 1/1/07

  OUS 100% Lilly

  	
   

  	
  Beginning 1/1/06

  OUS 100% Lilly

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

*Subject
to recharacterization as provided in Paragraph 3(c) of this Amendment.

***CONFIDENTIAL
TREATMENT REQUESTED

 

	
  Trial/Study
  Description

  	
   

  	
  US Split

  50/50

  	
   

  	
  OUS Split

  80L/20A

  	
   

  	
  Beginning 1/1/07

  OUS 100% Lilly

  	
   

  	
  Beginning 1/1/06

  OUS 100% Lilly

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
  X

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  
	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  X

  	
   

  

 

***CONFIDENTIAL
TREATMENT REQUESTED

 

 2Exhibit
10.42

The CORPORATEplan for
RetirementSM

EXECUTIVE PLAN

BASIC
PLAN DOCUMENT

IMPORTANT
NOTE

This document has not been approved by the Department
of Labor, the Internal Revenue Service or any other governmental entity.  An Adopting Employer must determine whether
the plan is subject to the Federal securities laws and the securities laws of
the various states.  An Adopting Employer
may not rely on this document to ensure any particular tax consequences or to
ensure that the Plan is “unfunded and maintained primarily for the purpose of
providing deferred compensation to a select group of management or highly
compensated employees” under the Employee Retirement Income Security Act with
respect to the Employer’s particular situation. 
Fidelity Management Trust Company, its affiliates and employees cannot
and do not provide legal or tax advice in connection with this document.  This document does not constitute legal or
tax advice and is not intended or written to be used, and it cannot be used by
any taxpayer, for the purposes of avoiding penalties that may be imposed on the
taxpayer.  This document should be
reviewed by the Employer’s attorney prior to adoption.

CORPORATEplan
for Retirement EXECUTIVE

BASIC PLAN DOCUMENT

ARTICLE 1

  ADOPTION AGREEMENT

ARTICLE 2

  DEFINITIONS

  2.01 -
Definitions

ARTICLE 3

  PARTICIPATION

  3.01 - Date
of Participation

  3.02 - Resumption of Participation Following Re employment

  3.03 - Cessation or Resumption of Participation Following a Change
in Status

ARTICLE 4

  CONTRIBUTIONS

  4.01 -
Deferral Contributions

  4.02 - Matching Contributions

  4.03 - Employer Contributions

  4.04 - Time of Making Contributions

ARTICLE 5

  PARTICIPANTS’ ACCOUNTS

  5.01 -
Individual Accounts

ARTICLE 6

  INVESTMENT OF CONTRIBUTIONS

  6.01 - Manner
of Investment

  6.02 - Investment Decisions

ARTICLE 7

  RIGHT TO BENEFITS

  7.01 - Normal
or Early Retirement

  7.02 - Death

  7.03 - Other Termination of Employment

  7.04 - Separate Account

  7.05 - Forfeitures

  7.06 - Adjustment for Investment Experience

  7.07 - Unforeseeable Emergency Withdrawals

  7.08 - Change in Control

ARTICLE 8

  DISTRIBUTION OF BENEFITS PAYABLE AFTER TERMINATION OF SERVICE

  8.01 -
Distribution of Benefits to Participants and Beneficiaries

  8.02 - Determination of Method of Distribution

  8.03 - Notice to Trustee

  8.04 - Time of Distribution

ARTICLE 9

  AMENDMENT AND TERMINATION

  9.01 - Amendment by Employer

  9.02 - Retroactive Amendments

  9.03 - Termination

  9.04 -
Distribution Upon Termination of the Plan

ARTICLE 10

  MISCELLANEOUS

  10.01 - Communication to Participants

  10.02 - Limitation of Rights

  10.03 - Nonalienability of Benefits

  10.04 - Facility of Payment

  10.05 - Information between Employer and Trustee

  10.06 - Notices

  10.07 -
Governing Law

ARTICLE 11

  PLAN ADMINISTRATION

  11.01 - Powers and responsibilities of the Administrator

  11.02 - Nondiscriminatory Exercise of Authority

  11.03 -
Claims and Review Procedures

PREAMBLE

It is
the intention of the Employer to establish herein an unfunded plan maintained
solely for the purpose of providing deferred compensation for a select group of
management or highly compensated employees as provided in ERISA.

Article
1.  Adoption Agreement.

Article
2.  Definitions.

2.01.  Definitions.

(a) Wherever used herein, the following terms have the
meanings set forth below, unless a different meaning is clearly required by the
context:

(1)  “Account” means an account established
on the books of the Employer for the purpose of recording amounts credited on
behalf of a Participant and any income, expenses, gains or losses included
thereon.

(2)  “Administrator” means the Employer
adopting this Plan, or other person designated by the Employer in Section
1.01(b).

(3)  “Adoption Agreement” means Article 1,
under which the Employer establishes and adopts or amends the Plan and
designates the optional provisions selected by the Employer.  The provisions of the Adoption Agreement
shall be an integral part of the Plan.

(4)  “Beneficiary” means the person or
persons entitled under Section 7.02 to receive benefits under the Plan upon the
death of a Participant.

(5)  “Bonus” means any performance-based
Compensation based on services performed for the Employer over a period of at
least 12 months.

(6)  “Change of Control” means a change in
the ownership or effective control of the Employer, or a substantial portion of
the Employer’s assets as defined in the regulations under Code Section 409A.

(7)  “Code” means the Internal Revenue Code
of 1986, as amended from time to time.

(8)  “Compensation” means for purposes of
Article 4 (Contributions) wages as defined in Section 3401(a) of the Code and
all other payments of compensation to an employee by the Employer (in the
course of the Employer’s trade or business) for which the Employer is required
to furnish the employee a written statement under Section 6041(d) and
6051(a)(3) of the Code, excluding any items elected by the Employer in Section
1.04, reimbursements or other expense allowances, fringe benefits (cash and
non-cash), moving expenses, deferred compensation and welfare benefits, but
including amounts that are not includable in the gross income of the
Participant under a salary reduction agreement by reason of the application of
Sections 125, 132(f)(4), 402(e)(3), 402(h) or 403(b) of the Code.  Compensation shall be determined without
regard to any rules under Section 3401(a) of the Code that limit the
remuneration included in wages based on the nature or location of the
employment or the services performed (such as the exception for agricultural
labor in Section 3401(a)(2) of the Code).

Compensation shall also include amounts deferred
pursuant to an election under Section 4.01.

In the case of any Self-Employed Individual or an
Owner-Employee, Compensation means the Self-Employed Individual’s Earned
Income.

(9)  “Earned Income” means the net earnings
of a Self-Employed Individual derived from the trade or business with respect
to which the Plan is established and for which the personal services of such
individual are a material income-providing factor, excluding any items not
included in gross income and the deductions allocated to such items, except
that for taxable years beginning after December 31, 1989 net earnings shall be
determined

with regard to the deduction allowed under Section
164(f) of the Code, to the extent applicable to the Employer.  Net earnings shall be reduced by
contributions of the Employer to any qualified plan, to the extent a deduction
is allowed to the Employer for such contributions under Section 404 of the Code.

(10)  “Employee” means any employee of the
Employer, Self-Employed Individual or Owner-Employee.

(11)  “Employer” means the employer named in
Section 1.02(a) and any Related Employers designated in Section 1.02(b).

(12)  “Employment Commencement Date” means
the date on which the Employee first performs an Hour of Service.

(13)  “Entry Date” means the date(s)
designated in Section 1.03(b).

(14)  “ERISA” means the Employee Retirement
Income Security Act of 1974, as from time to time amended.

(15)  “Fund Share” means the share, unit, or
other evidence of ownership in a Permissible Investment.

(16)  “Hour of Service” means, with respect
to any Employee,

(A)  Each
hour for which the Employee is directly or indirectly paid, or entitled to
payment, for the performance of duties for the Employer or a Related Employer,
each such hour to be credited to the Employee for the computation period in
which the duties were performed;

(B)  Each
hour for which the Employee is directly or indirectly paid, or entitled to
payment, by the Employer or Related Employer (including payments made or due
from a trust fund or insurer to which the Employer contributes or pays
premiums) on account of a period of time during which no duties are performed
(irrespective of whether the employ-ment relationship has terminated) due to
vacation, holiday, illness, incapacity, disability, layoff, jury duty, military
duty, or leave of absence, each such hour to be credited to the Employee for
the Eligibility Computation Period in which such period of time occurs, subject
to the following rules:

(i)  No
more than 501 Hours of Service shall be credited under this paragraph (B) on
account of any single continuous period during which the Employee performs no
duties;

(ii)  Hours
of Service shall not be credited under this paragraph (B) for a payment which
solely reimburses the Employee for medically-related expenses, or which is made
or due under a plan maintained solely for the purpose of complying with
applicable workmen’s compensation, unemployment compensation or disability
insurance laws; and

(iii)  If
the period during which the Employee performs no duties falls within two or
more computation periods and if the payment made on account of such period is
not calculated on the basis of units of time, the Hours of Service credited
with respect to such period shall be allocated between not more than the first
two such computation periods on any reasonable basis consistently applied with
respect to similarly situated Employees; and

(C)  Each
hour not counted under paragraph (A) or (B) for which back pay, irrespective of
mitigation of damages, has been either awarded or agreed to be paid by the
Employer or a Related Employer, each such hour to be credited to the Employee
for the computation period to which the award or agreement pertains rather than
the computation period in which the award agreement or payment is made.

For purposes of
determining Hours of Service, Employees of the Employer and of all Related
Employers will be treated as employed by a single employer.  For purposes of paragraphs (B) and (C) above,
Hours of Service will be calculated in accordance with the provisions of
Section 2530.200b-2(b) of the Department of Labor regulations, which are
incorporated herein by reference.

Solely for purposes of
determining whether a break in service for participation purposes has occurred
in a computation period, an individual who is absent from work for maternity or
paternity reasons shall receive credit for the hours of service which would
otherwise been credited to such individual but for such absence, or in any case
in which such hours cannot be determined, 8 hours of service per day of such
absence.  For purposes of this paragraph,
an absence from work for maternity reasons means an absence (1) by reason of
the pregnancy of the individual, (2) by reason of a birth of a child of the
individual, (3) by reason of the placement of a child with the individual in
connection with the adoption

of such child by such individual, or (4) for purposes
of caring for such child for a period beginning immediately following such
birth or placement.  The hours of service
credited under this paragraph shall be credited (1) in the computation period
in which the absence begins if the crediting is necessary to prevent a break in
service in that period, or (2) in all other cases, in the following computation
period.

(17)  “Key
Employee” means a Participant who is key employee pursuant to Code Section
416(i), without regard to paragraph (5) thereof.  A Participant will not be considered a Key
Employee unless the Employer is a corporation which has any of its stock
publicly traded according to Code Section 409A and regulations thereunder.

(18) “Normal Retirement Age” means the normal
retirement age specified in Section 1.07(f) of the Adoption Agreement.

(19)  “Owner-Employee”
means, if the Employer is a sole proprietorship, the individual who is the sole
proprietor, or, if the Employer is a partnership, a partner who owns more than
10 percent of either the capital interest or the profits interest of the
partnership.

(20)  “Participant”
means any Employee who participates in the Plan in accordance with Article 3
hereof.

(21)  “Permissible
Investment” means the investments specified by the Employer as available for
investment of assets of the Trust and agreed to by the Trustee. The Permissible
Investments under the Plan shall be listed in the Service Agreement.

(22)  “Plan”
means the plan established by the Employer as set forth herein as a new plan or
as an amendment to an existing plan, by executing the Adoption Agreement,
together with any and all amendments hereto.

(23)  “Plan Year”
means the 12-consecutive-month period designated by the Employer in Section
1.01(c).

(24)  “Related
Employer” means any employer other than the Employer named in Section 1.02(a),
if the Employer and such other employer are members of a controlled group of
corporations (as defined in Section 414(b) of the Code) or an affiliated
service group (as defined in Section 414(m)), or are trades or businesses
(whether or not incorporated) which are under common control (as defined in
Section 414(c)), or such other employer is required to be aggregated with the
Employer pursuant to regulations issued under Section 414(o).

(25) “Self-Employed
Individual” means an individual who has Earned Income for the taxable year from
the Employer or who would have had Earned Income but for the fact that the
trade or business had no net profits for the taxable year.

(26)  “Service
Agreement” means the agreement between the Employer and Trustee regarding the
arrangement between the parties for recordkeeping services with respect to the
Plan.

(27)  “Trust” means the trust created by the
Employer.

(28)  “Trust
Agreement” means the agreement between the Employer and the Trustee, as set
forth in a separate agreement, under which assets are held, administered, and
managed subject to the claims of the Employer’s creditors in the event of the
Employer’s insolvency, until paid to Plan Participants and their Beneficiaries
as specified in the Plan.

(29)  “Trust
Fund” means the property held in the Trust by the Trustee.

(30)  “Trustee”
means the corporation or individual(s) appointed by the Employer to administer
the Trust in accordance with the Trust Agreement.

(31) “Years of Service for Vesting” means, with
respect to any Employee, the number of whole years of his periods of service
with the Employer or a Related Employer (the elapsed time method to compute
vesting service), subject to any exclusions elected by the Employer in Section
1.07(c).  An Employee will receive credit
for the aggregate of all time period(s) commencing with the Employee’s
Employment Commencement Date and ending on the date a break in service begins,
unless any such years are excluded by Section 1.07(c).  An Employee will also receive credit for any
period of severance of less than 12 consecutive months.  Fractional periods of a year will be
expressed in terms of days.

  In the case of
a Participant who has 5 consecutive 1-year breaks in service, all years of
service after such breaks in service will be disregarded for the purpose of
vesting the Employer-derived account balance that accrued before such breaks,
but both pre-break and post-break service will count for the purposes of
vesting the Employer-derived account balance that accrues after such
breaks.  Both accounts will share in the
earnings and losses of the fund.

  In the case of
a Participant who does not have 5 consecutive 1-year breaks in service, both
the pre-break and post-break service will count in vesting both the pre-break
and post-break employer-derived account balance.

  A break in
service is a period of severance of at least 12 consecutive months.  Period of severance is a continuous period of
time during which the Employee is not employed by the Employer.  Such period begins on the date the Employee
retires, quits or is discharged, or if earlier, the 12-month anniversary of the
date on which the Employee was otherwise first absent from service.

  In the case of
an individual who is absent from work for maternity or paternity reasons, the
12-consecutive month period beginning on the first anniversary of the first
date of such absence shall not constitute a break in service.  For purposes of this paragraph, an absence
from work for maternity or paternity reasons means an absence (1) by reason of
the pregnancy of the individual, (2) by reason of the birth of a child of the
individual, (3) by reason of the placement of a child with the individual in
connection with the adoption of such child by such individual, or (4) for
purposes of caring for such child for a period beginning immediately following
such birth or placement.

  If the Plan
maintained by the Employer is the plan of a predecessor employer, an Employee’s
Years of Service for Vesting shall include years of service with such
predecessor employer.  In any case in
which the Plan maintained by the Employer is not the plan maintained by a
predecessor employer, service for such predecessor shall be treated as service
for the Employer to the extent provided in Section 1.08.

(b) Pronouns used in the
Plan are in the masculine gender but include the feminine gender unless the
context clearly indicates otherwise.

Article
3.  Participation.

3.01.  Date of Participation.  An eligible Employee (as
set forth in Section 1.03(a)) who has filed an election pursuant to Section
4.01 will become a Participant in the Plan on the first Entry Date coincident
with or following the date on which such election would otherwise become
effective, as determined under Section4.01.

3.02.  Resumption of Participation Following
Reemployment.  If a
Participant ceases to be an Employee and thereafter returns to the employ of
the Employer he will again become a Participant as of an Entry Date following
the date on which he completes an Hour of Service for the Employer following
his re employment, if he is an eligible Employee as defined in Section 1.03(a),
and has filed an election pursuant to Section 4.01.

3.03.  Cessation or Resumption of Participation
Following a Change in Status.  If any Participant continues in the employ of
the Employer or Related Employer but ceases to be an eligible Employee as
defined in Section 1.03(a), the individual shall continue to be a Participant
until the entire amount of his benefit is distributed; however, the individual
shall not be entitled to make Deferral Contributions or receive an allocation
of Matching or Employer Contributions during the period that he is not an
eligible Employee.  Such Participant
shall continue to receive credit for service completed during the period for
purposes of determining his vested interest in his Accounts.  In the event that the individual subsequently
again becomes an eligible Employee, the individual shall resume full
participation in accordance with Section 3.01.

Article
4.  Contributions.

4.01.
Deferral Contributions.  Each
Participant may elect to execute a salary reduction agreement with the Employer
to reduce his Compensation by a specified percentage, not exceeding the
percentage set forth in Section 1.05(a) and equal to a whole number multiple of
one (1) percent, per payroll period, subject to any election regarding Bonuses,
as set out in Subsection 1.05(a)(2). 
Such agreement shall become effective on the first day of the period as
set forth in the Participant’s election.  The election will be effective to defer
Compensation relating to all services performed in a calendar year subsequent
to the filing of such an election, subject to any election regarding Bonuses,
as set out in Subsection 1.05(a)(2).  An
election once made will remain in effect until a new election is made;
provided, however that such an election choosing a distribution date pursuant
to 1.06(b)(1)(B) will only be effective for the Plan Year indicated.  A new election will be effective as of the
first day of the following calendar year and will apply only to Compensation
payable with respect to services rendered after such date, except that a
separate election made pursuant to

Section 1.05(a)(2) will
be effective immediately if made no later than 6 months before the end of the
period during which the services on which the Bonus is based are
performed.  If the Employer has selected
1.05(a)(2), no amount will be deducted from Bonuses unless the Participant has
made a separate election.  Amounts
credited to a Participant’s account prior to the effective date of any new
election will not be affected and will be paid in accordance with that prior
election.  The Employer shall credit an
amount to the account maintained on behalf of the Participant corresponding to
the amount of said reduction.  Under no
circumstances may a salary reduction agreement be adopted retroactively. To the
extent permitted in regulations under Code Section 409A, a Participant may
revoke a salary reduction agreement for a calendar year during that year,
provided, however, that such revocation shall apply only to Compensation not
yet earned.  In that event, the
Participant shall be precluded from electing to defer future Compensation
hereunder during the calendar year to which the revocation applies.  Notwithstanding the above, in the calendar
year in which the Plan first becomes effective or in the year in which the
Participant first becomes eligible to participate, an election to defer
compensation may be made within 30 days after the Participant is first eligible
or the Plan is first effective, which election shall be effective with respect
to Compensation payable with respect to services rendered after the date of the
election.

4.02.  Matching Contributions.  If so provided by the Employer in Section
1.05(b), the Employer shall make a “Matching Contribution” to be credited to
the account maintained on behalf of each Participant who had “Deferral
Contributions” pursuant to Section 4.01 made on his behalf during the year and
who meets the requirement, if any, of Section 1.05(b)(3).  The amount of the “Matching Contribution”
shall be determined in accordance with Section 1.05(b).

4.03.  Employer Contributions.   If so provided by the
Employer in Section 1.05(c)(1), the Employer shall make an “Employer
Contribution” to be credited to the account maintained on behalf of each
Participant who meets the requirement, if any, of Section 1.05(c)(3) in the
amount required by Section 1.05(c)(1). 
If so provided by the Employer in Section 1.05(c)(2), the Employer may
make an “Employer Contribution” to be credited to the account maintained on
behalf of any Participant in such an amount as the Employer, in its sole
discretion, shall determine.  In making “Employer
Contributions” pursuant to Section 1.05(c)(2), the Employer shall not be
required to treat all Participants in the same manner in determining such
contributions and may determine the “Employer Contribution” of any Participant
to be zero.

4.04.  Time of Making Contributions.  The Employer shall remit contributions deemed
made hereunder to the Trust as soon as practicable after such contributions are
deemed made under the terms of the Plan.

Article
5.  Participants’ Accounts.

5.01.  Individual Accounts.  The Administrator will establish and maintain
an Account for each Participant, which will reflect Matching, Employer and
Deferral Contributions credited to the Account on behalf of the Participant and
earnings, expenses, gains and losses credited thereto, and deemed investments
made with amounts in the Participant’s Account. 
The Administrator will establish and maintain such other accounts and
records as it decides in its discretion to be reasonably required or
appropriate in order to discharge its duties under the Plan.  Participants will be furnished statements of
their Account values at least once each Plan Year.  The Administrator shall provide the Trustee
with information on the amount credited to the separate account of each
Participant maintained by the Administrator in its records.

Article
6.  Investment of Contributions.

6.01.  Manner of Investment.  All amounts credited to the Accounts of
Participants shall be treated as though invested and reinvested only in
eligible investments selected by the Employer in the Service Agreement.

6.02.  Investment Decisions. Investments
in which the Accounts of Participants shall be treated as invested and
reinvested shall be directed by the Employer or by each Participant, or both,
in accordance with the Employer’s election in Section 1.11(a).

(a)  All dividends, interest, gains and
distributions of any nature that would be earned in respect of Fund Shares in
which the Account is treated as investing shall be credited to the Account as
though reinvested in additional shares of that Permissible Investment.

(b)  Expenses that would be attributable to
the acquisition of investments shall be charged to the Account of the
Participant for which such investment is treated as having been made.

Article
7.  Right to Benefits.

7.01.  Normal or Early Retirement.  If provided by the Employer in Section
1.07(e), each Participant who attains his Normal Retirement Age or Early
Retirement Age will have a nonforfeitable interest in his Account in accordance
with the vesting schedule(s) elected in Section 1.07.  If a Participant retires on or after
attainment of Normal or Early Retirement Age, such retirement is referred to as
a normal retirement.  On or after his
normal retirement, the balance of the Participant’s Account, plus any amounts
thereafter credited to his Account, subject to the provisions of Section 7.06,
will be distributed to him in accordance with Article 8.

 If provided by the Employer in Section 1.07, a
Participant who separates from service before satisfying the age requirements
for early retirement, but has satisfied the service requirement will be
entitled to the distribution of his Account, subject to the provisions of
Section 7.06, in accordance with Article 8, upon satisfaction of such age
requirement.

7.02.  Death.  If a Participant dies before the distribution
of his Account has commenced, or before such distribution has been completed,
his Account shall become vested in accordance with the vesting schedule(s)
elected in Section 1.07 and his designated Beneficiary or Beneficiaries will be
entitled to receive the balance or remaining balance of his Account, plus any
amounts thereafter credited to his Account, subject to the provisions of
Section 7.06.  Distribution to the
Beneficiary or Beneficiaries will be made in accordance with Article 8.  A distribution to a beneficiary of a Key
Employee is not considered to be a distribution to a Key Employee for purposes
of Sections 1.06 and 7.08.

 A Participant may designate a Beneficiary or
Beneficiaries, or change any prior designation of Beneficiary or Beneficiaries,
by giving notice to the Administrator on a form designated by the
Administrator.  If more than one person
is designated as the Beneficiary, their respective interests shall be as
indicated on the designation form.

 A copy of the death certificate or other
sufficient documentation must be filed with and approved by the
Administrator.  If upon the death of the
Participant there is, in the opinion of the Administrator, no designated
Beneficiary for part or all of the Participant’s Account, such amount will be
paid to his surviving spouse or, if none, to his estate (such spouse or estate
shall be deemed to be the Beneficiary for purposes of the Plan).  If a Beneficiary dies after benefits to such
Beneficiary have commenced, but before they have been completed, and, in the
opinion of the Administrator, no person has been designated to receive such
remaining benefits, then such benefits shall be paid to the deceased
Beneficiary’s estate.

7.03.  Other Termination of Employment.  If provided by the Employer in Section 1.07,
if a Participant terminates his employment for any reason other than death or
normal retirement, he will be entitled to a termination benefit equal to (i)
the vested percentage(s) of the value of the Matching and Employer
Contributions to his Account, as adjusted for income, expense, gain, or loss,
such percentage(s) determined in accordance with the vesting schedule(s)
selected by the Employer in Section 1.07, and (ii) the value of the Deferral
Contributions to his Account as adjusted for income, expense, gain or
loss.  The amount payable under this
Section 7.03 will be subject to the provisions of Section 7.06 and will be
distributed in accordance with Article 8. 
For purposes of the Plan, a termination of employment is a separation
from service as defined pursuant to Code Section 409A and regulations
thereunder.

7.04.  Separate Account.  If a distribution from a Participant’s
Account has been made to him at a time when he has a nonforfeitable right to
less than 100 percent of his Account, the vesting schedule in Section 1.07 will
thereafter apply only to amounts in his Account attributable to Matching and
Employer Contributions allocated after such distribution.  The balance of his Account immediately after
such distribution will be transferred to a separate account that will be
maintained for the purpose of determining his interest therein according to the
following provisions.

 At any relevant time prior to a forfeiture of
any portion thereof under Section 7.05, a Participant’s nonforfeitable interest
in his Account held in a separate account described in the preceding paragraph
will be equal to P(AB + (RxD))-(RxD), where P is the nonforfeitable percentage
at the relevant time determined under Section 7.05; AB is the account balance
of the separate account at the relevant time; D is the amount of the
distribution; and R is the ratio of the account balance at the relevant time to
the account balance after distribution. 
Following a forfeiture of any portion of such separate account under
Section 7.05 below, any balance in the Participant’s separate account will
remain fully vested and nonforfeitable.

7.05.  Forfeitures.  If a Participant terminates his employment,
any portion of his Account (including any amounts credited after his
termination of employment) not payable to him under Section 7.03 will be
forfeited by him.

7.06.  Adjustment for Investment Experience.  If any distribution under this Article 7 is
not made in a single payment, the amount remaining in the Account after the
distribution will be subject to adjustment until distributed to reflect the
income and gain or loss on the investments in which such amount is treated as
invested and any expenses properly charged under the Plan to such amounts.

7.07.
Unforeseeable Emergency Withdrawals.  Subject to the provisions of Article 8, a
Participant shall not be permitted to withdraw his Account (and earnings
thereon) prior to retirement or termination of employment, except that, to the
extent permitted under Section 1.09, a Participant may apply to the Administrator
to withdraw some or all of his Account if such withdrawal is made on account of
an unforeseeable emergency as determined by the Administrator in accordance
with the requirements of and subject to the limitations provided within Code
Section 409A and regulations thereunder.

7.08.
Change in Control Distributions.  If the Employer has elected to apply Section
1.06(c), then, upon a Change in Control, notwithstanding any other provision of
the Plan to the contrary, all Participants shall have a nonforfeitable right to
receive the entire amount of their account balances under the Plan.  All distributions due to a Change in Control
shall be paid out to Participants as soon as administratively practicable,
except that any such distribution to a Key Employee who has terminated
employment pursuant to Section 7.03 shall not be earlier than the 1st day of
the seventh month following that Key Employee’s termination of employment.

Article
8.  Distribution of Benefits.

8.01.  Form of Distribution of Benefits to
Participants and Beneficiaries.  The Plan provides for distribution as a lump
sum to be paid in cash on the date specified by the Employer in Section 1.06
pursuant to the method provided in Section 8.02.  If elected by the Employer in Section 1.10
and specified in the Participant’s deferral election, the distribution will be
paid through a systematic withdrawal plan (installments) for a time period not
exceeding 10 years beginning on the date specified by the Employer in Section
1.06.

8.02.
Events Requiring Distribution of Benefits
to Participants and Beneficiaries.

(a) If elected by the
Employer in Section 1.06(a), the Participant will receive a distribution upon
the earliest of the events specified by the Employer in Section 1.06(a),
subject to the provisions of Section 7.08, and at the time indicated in Section
1.06(a)(2).  If the Participant dies
before any event in Section 1.06(a) occurs, the Participant shall be considered
to have terminated employment and the Participant’s benefit will be paid to the
Participant’s Beneficiary in the same form and at the same time as it would
have been paid to the Participant pursuant to this Article 8.

(b) If elected by the
Employer in Section 1.06(b), the Participant will receive a distribution of all
amounts not deferred pursuant to Section 1.06(b)(1)(B) (and earnings
attributable to those amounts) upon termination of employment, subject to the
delay applicable to Key Employees described therein, as applicable.  If elected by the Employer in Section
1.06(b)(1)(B), the Participant shall have the election to receive distributions
of amounts deferred pursuant to Section 4.01 (and earnings attributable to
those amounts) after a date specified by the Participant in his deferral
election which is at least 12 months after the first day of the calendar year
in which such amounts would be earned. 
Amounts distributed to the Participant pursuant to Section 1.06(b) shall
be distributed at the time indicated in Section 1.06(b)(2).   Subject to the provisions of Section 7.08,
the Participant shall receive a distribution in the form provided in Section
8.01.  If the Participant dies before any
event in Section 1.06(a) occurs, the Participant shall be considered to have
terminated employment and the Participant’s benefit will be paid to the
Participant’s Beneficiary in the same form and at the same time as it would
have been paid to the Participant pursuant to this Article 8.  However, if the Participant dies before the
date specified by the Participant in an election pursuant to Section
1.06(b)(1)(B), then the Participant’s benefit shall be paid to the Participant’s
Beneficiary in the form provided in Section 8.01 as if the Participant had
elected to be paid at termination of employment.

8.03.  Determination of Method of Distribution.  The Participant will determine the method of
distribution of benefits to himself and his Beneficiary, subject to the
provisions of Section 8.02.  Such
determination will be made at the time the Participant makes a deferral
election.  A Participant’s election
cannot be altered, except, if elected by the Employer in Section 1.10(b), if
the Participant’s balance falls below the level described in regulations under
Code Section 409A, the Participant’s benefit payable due to termination of
employment will be distributed in a lump sum rather than installments.

(a) When Section 1.06(a) has been elected by the
Employer.   The distribution period
specified in a Participant’s first deferral election specifying distribution
under a systematic withdrawal plan shall apply to all subsequent elections of
distributions under a systematic withdrawal plan made by the Participant.  Once a Participant has made an election for
the method of distribution, that election shall be effective for all
contributions made on behalf of the Participant attributable to any Plan Year
after that election was made and before the Plan Year for which that election
has been altered in the manner prescribed by the Administrator.  If the Participant does not designate in the
manner prescribed by the Administrator the method of distribution, such method
of distribution shall be a lump sum at termination of employment.

(b)  When Section 1.06(b) has
been elected by the Employer.  The
distribution period for distributions under a systematic withdrawal plan shall
be specified in each Participant’s contribution election selecting payments
under a systematic withdrawal plan.  If
the Participant does not designate in the manner prescribed by the
Administrator the method of distribution, such method of distribution for all
such contributions shall be a lump sum at termination of employment.

8.04.  Notice to Trustee.  The Administrator will notify the Trustee,
pursuant to the method stated in the Trust Agreement for providing direction,
whenever any Participant or Beneficiary is entitled to receive benefits under
the Plan.  The Administrator’s notice
shall indicate the form, amount and frequency of benefits that such Participant
or Beneficiary shall receive.

8.05.  Time of Distribution.  In no event will distribution to a
Participant be made later than the date specified by the Participant in his
salary reduction agreement. All distributions will be made as soon as
administratively feasible following the distribution date specified in Section
1.06 or Section 7.08, if applicable.

Article
9.  Amendment and Termination.

9.01  Amendment by Employer.  The Employer reserves the authority to amend
the Plan by filing with the Trustee an amended Adoption Agreement, executed by
the Employer only, on which said Employer has indicated a change or changes in
provisions previously elected by it. 
Such changes are to be effective on the effective date of such amended
Adoption Agreement.  Any such change notwithstanding,
no Participant’s Account shall be reduced by such change below the amount to
which the Participant would have been entitled if he had voluntarily left the
employ of the Employer immediately prior to the date of the change.  The Employer may from time to time make any
amendment to the Plan that may be necessary to satisfy the Code or ERISA.  The Employer’s board of directors or other
individual specified in the resolution adopting this Plan shall act on behalf
of the Employer for purposes of this Section 9.01.

9.02  Retroactive Amendments.  An amendment made by the Employer in
accordance with Section 9.01 may be made effective on a date prior to the first
day of the Plan Year in which it is adopted if such amendment is necessary or
appropriate to enable the Plan and Trust to satisfy the applicable requirements
of the Code or ERISA or to conform the Plan to any change in federal law or to
any regulations or ruling thereunder. 
Any retroactive amendment by the Employer shall be subject to the
provisions of Section 9.01.

9.03.  Termination.  The Employer has adopted the Plan with the
intention and expectation that contributions will be continued
indefinitely.  However, said Employer has
no obligation or liability whatsoever to maintain the Plan for any length of
time and may discontinue contributions under the Plan or terminate the Plan at
any time by written notice delivered to the Trustee without any liability
hereunder for any such discontinuance or termination.

9.04.  Distribution upon Termination of the Plan.  Upon termination of the Plan, no further
Deferral, Employer or Matching Contributions shall be made under the Plan, but
Accounts of Participants maintained under the Plan at the time of termination
shall continue to be governed by the terms of the Plan until paid out in
accordance with the terms of the Plan.

Article
10.  Miscellaneous.

10.01.  Communication to Participants.  The Plan will be communicated to all
Participants by the Employer promptly after the Plan is adopted.

10
02.  Limitation of Rights.  Neither the establishment of the Plan and the
Trust, nor any amendment thereof, nor the creation of any fund or account, nor
the payment of any benefits, will be construed as giving to any Participant or
other person any legal or equitable right against the Employer, Administrator
or Trustee, except as provided herein; and in no event will the terms of
employment or service of any Participant be modified or in any way affected
hereby.

10.03.  Nonalienability of Benefits.  The benefits provided hereunder will not be
subject to alienation, assignment, garnishment, attachment, execution or levy
of any kind, either voluntarily or involuntarily, and any attempt to cause such
benefits to be so subjected will not be recognized, except to such extent as
may be required by law.

10
04.  Facility of Payment.  In the event the Administrator determines, on
the basis of medical reports or other evidence satisfactory to the
Administrator, that the recipient of any benefit payments under the Plan is
incapable of handling his affairs by reason of minority, illness, infirmity or
other incapacity, the Administrator may disburse such payments, or direct the
Trustee to disburse such payments, as applicable, to a person or institution
designated by a court

which has
jurisdiction over such recipient or a person or institution otherwise having
the legal authority under State law for the care and control of such
recipient.  The receipt by such person or
institution of any such payments shall be complete acquittance therefore, and
any such payment to the extent thereof, shall discharge the liability of the
Trust for the payment of benefits hereunder to such recipient.

10.05.  Information between Employer and Trustee.  The Employer agrees to furnish the Trustee,
and the Trustee agrees to furnish the Employer with such information relating
to the Plan and Trust as may be required by the other in order to carry out
their respective duties hereunder, including without limitation information
required under the Code or ERISA and any regulations issued or forms adopted
thereunder.

10.06.  Notices.  Any notice or other communication in
connection with this Plan shall be deemed delivered in writing if addressed as
provided below and if either actually delivered at said address or, in the case
of a letter, three business days shall have elapsed after the same shall have
been deposited in the United States mails, first-class postage prepaid and
registered or certified:

(a) If to the Employer or Administrator, to it at the
address set forth in the Adoption Agreement, to the attention of the person
specified to receive notice in the Adoption Agreement;

(b) If to the Trustee, to it at the address set forth
in the Trust Agreement;

or, in each case
at such other address as the addressee shall have specified by written notice
delivered in accordance with the foregoing to the addressor’s then effective
notice address.

10.07.  Governing Law.  The Plan and the accompanying Adoption
Agreement will be construed, administered and enforced according to ERISA, and
to the extent not preempted thereby, the laws of the Commonwealth of
Massachusetts, without regard to its conflicts of law principles.

Article
11.  Plan Administration.

11.01.  Powers and responsibilities of the
Administrator.  The
Administrator has the full power and the full responsibility to administer the
Plan in all of its details, subject, however, to the applicable requirements of
ERISA.  The Administrator’s powers and
responsibilities include, but are not limited to, the following:

(a) To make and enforce such rules and regulations as
it deems necessary or proper for the efficient administration of the Plan;

(b) To interpret the Plan, its interpretation thereof
in good faith to be final and conclusive on all persons claiming benefits under
the Plan;

(c) To decide all questions concerning the Plan and
the eligibility of any person to participate in the Plan;

(d) To administer the claims and review procedures
specified in Section 11.03;

(e) To compute the amount of benefits which will be
payable to any Participant, former Participant or Beneficiary in accordance with
the provisions of the Plan;

(f) To determine the person or persons to whom such
benefits will be paid;

(g) To authorize the payment of benefits;

(h) To comply with any applicable reporting and
disclosure requirements of Part 1 of Subtitle B of Title I of ERISA;

(i) To appoint such agents, counsel, accountants, and
consultants as may be required to assist in administering the Plan;

(j) By written instrument, to allocate and delegate
its responsibilities, including the formation of an Administrative Committee to
administer the Plan;

11.02.  Nondiscriminatory Exercise of Authority.  Whenever, in the administration of the Plan,
any discretionary action by the Administrator is required, the Administrator
shall exercise its authority in a nondiscriminatory manner so that all persons
similarly situated will receive substantially the same treatment.

11.03.  Claims and Review Procedures.

(a) Claims Procedure.  If any person believes he is being denied any
rights or benefits under the Plan, such person may file a claim in writing with
the Administrator.  If any such claim is
wholly or partially denied, the Administrator will notify such person of its
decision in writing.  Such notification
will contain (i) specific reasons for the denial, (ii) specific reference to
pertinent Plan provisions, (iii) a description of any additional material or
information necessary for such person to perfect such claim and an explanation
of why such material or information is necessary, and (iv) information as to
the steps to be taken if the person wishes to submit a request for review,
including a statement of the such person’s right to bring a civil action under
Section 502(a) of ERISA following as adverse determination upon review.  Such notification will be given within 90
days after the claim is received by the Administrator (or within 180 days, if
special circumstances require an extension of time for processing the claim,
and if written notice of such extension and circumstances is given to such
person within the initial 90-day period).

 If the claim
concerns disability benefits under the Plan, the Plan Administrator must notify
the claimant in writing within 45 days after the claim has been filed in order
to deny it.  If special circumstances
require an extension of time to process the claim, the Plan Administrator must
notify the claimant before the end of the 45-day period that the claim may take
up to 30 days longer to process.  If
special circumstances still prevent the resolution of the claim, the Plan
Administrator may then only take up to another 30 days after giving the
claimant notice before the end of the original 30-day extension.  If the Plan Administrator gives the claimant
notice that the claimant needs to provide additional information regarding the
claim, the claimant must do so within 45 days of that notice.

(b) Review Procedure.  Within 60 days after the date on which a
person receives a written notice of a denied claim (or, if applicable, within
60 days after the date on which such denial is considered to have occurred),
such person (or his duly authorized representative) may (i) file a written
request with the Administrator for a review of his denied claim and of
pertinent documents and (ii) submit written issues and comments to the
Administrator.  This written request may
include comments, documents, records, and other information relating to the
claim for benefits.  The claimant shall
be provided, upon the claimant’s request and free of charge, reasonable access
to, and copies of, all documents, records, and other information relevant to
the claim for benefits.  The review will
take into account all comments, documents, records, and other information
submitted by the claimant relating to the claim, without regard to whether such
information was submitted or considered in the initial benefit
determination.  The Administrator will
notify such person of its decision in writing. 
Such notification will be written in a manner calculated to be understood
by such person and will contain specific reasons for the decision as well as
specific references to pertinent Plan provisions.  The decision on review will be made within 60
days after the request for review is received by the Administrator (or within
120 days, if special circumstances require an extension of time for processing
the request, such as an election by the Administrator to hold a hearing, and if
written notice of such extension and circumstances is given to such person
within the initial 60-day period). The extension notice shall indicate the
special circumstances requiring an extension of time and the date by which the
Plan expects to render the determination on review.

 If the initial
claim was for disability benefits under the Plan and has been denied by the
Plan Administrator, the claimant will have 180 days from the date the claimant
received notice of the claim’s denial in which to appeal that decision.  The review will be handled completely
independently of the findings and decision made regarding the initial claim and
will be processed by an individual who is not a subordinate of the individual
who denied the initial claim.  If the
claim requires medical judgment, the individual handling the appeal will
consult with a medical professional whom was not consulted regarding the
initial claim and who is not a subordinate of anyone consulted regarding the
initial claim and identify that medical professional to the claimant.

 The Plan
Administrator shall provide the claimant with written notification of a plan’s
benefit determination on review.  In the
case of an adverse benefit determination, the notification shall set forth, in
a manner calculated to be understood by the claimant – the specific reason or
reasons for the adverse determinations, reference to the specific plan
provisions on which the benefit determination is based, a statement that the
claimant is entitled to receive, upon the claimant’s request and free of
charge, reasonable access to, and copies of, all documents, records, and other
information relevant to the claim for benefits.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]